Company profile: AM-Pharma
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapeutics focused on inflammatory and infectious diseases, developing and commercializing products based on endogenous proteins, including ilofotase alfa, a recombinant alkaline phosphatase under development to prevent cardiac surgery-associated renal damage and as enzyme replacement therapy for hypophosphatasia.
Products and services
- Endogenous Protein-Based Therapeutics Development: AM-Pharma architects pre-clinical and clinical-stage programs delivering novel therapeutics for inflammatory and infectious diseases using endogenous proteins
- Ilofotase alfa for CSA-RD: A recombinant alkaline phosphatase developed as preventive treatment for renal damage in those undergoing cardiac surgery
- Ilofotase alfa for HPP: A recombinant alkaline phosphatase engineered as enzyme replacement therapy for hypophosphatasia, a rare disease affecting bone mineralization and muscle strength
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AM-Pharma
Redx Pharma
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development advancing clinical-stage assets Zelasudil (ROCK2 inhibitor for idiopathic pulmonary fibrosis and fibrotic diseases), Zamaporvint (Porcupine inhibitor for Wnt-ligand driven cancer), RXC008 (GI-targeted pan-ROCK for fibrostenotic Crohn's), and a Drug Discovery Engine supporting programs in fibrosis and oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Redx Pharma company profile →
Chronos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of age-related disease drug development, advancing SFX-01, a sulforaphane-based stable tablet for oncology and neurodevelopmental disorders; a highly selective orexin 1 receptor antagonist for addictive behaviors including binge eating disorder and alcohol use disorder; and an atypical DAT inhibitor for fatigue and narcolepsy, plus licensing and partnership collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chronos Therapeutics company profile →
CorMedix
HQ: United States
Website
- Description: Provider of specialty pharmaceutical products targeting cardiac, renal, and infectious diseases. Offers DefenCath, a catheter lock solution with taurolidine and heparin to reduce catheter-related bloodstream infections in adult patients with kidney failure on chronic hemodialysis via central venous catheter.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CorMedix company profile →
Athersys
HQ: United States
Website
- Description: Provider of an adult-derived, off-the-shelf stem cell therapy platform, MultiStem, for neurological, inflammatory and immune, cardiovascular, and other critical care indications. Conducts clinical trials and programs including MASTERS-2 and TREASURE for stroke, and AMI, PVD, and congestive heart failure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Athersys company profile →
Oxford Pharmascience
HQ: United Kingdom
Website
- Description: Provider of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take, licensing its technologies and dossiers to a network of partners rather than manufacturing or selling directly to consumers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford Pharmascience company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AM-Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AM-Pharma
2.2 - Growth funds investing in similar companies to AM-Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AM-Pharma
4.2 - Public trading comparable groups for AM-Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →